Xenetic Biosciences, Inc. Reports Full Year 2022 Financial Results and Provides Business Update

Author's Avatar
Mar 23, 2023

- Year marked by transformational strategic license of the DNase oncology platform and shift in focus to treatment of locally advanced or metastatic solid tumors